HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Betta Pharmaceuticals - Insights on Products and Concerns

Jiangsu Hengrui Medicine (600276.CH) - Insights on Recent Pullback and Future Business Prospects

WuXi AppTec (2359.HK) - The Certainties and the Uncertainties

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Hansoh Pharmaceutical Group  / Equity Bottom-Up

<p>When it comes to <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a>, people would  also mention <a href="https://www.smartkarma.com/entities/hansoh-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:23675:1" rel="noopener">Hansoh Pharmaceutical (3692 HK)</a>, because its chairlady and CEO Zhong Huijuan is the wife of Hengrui’s Sun Piaoyang. Previously, Hansoh started with generic drugs (mainly first-to-market generic drugs), and has several blockbuster varieties with annual sales of more than RMB1 billion, such as zefei, pulaile, oulanning and so on. After more than 20 years of development, the Company has tablished a broad, diversified and leading drug portfolio in central nervous system (“CNS”) diseases, oncology, anti-infectives and diabetes. This article mainly analyzed the core products, the pipeline, the key risks, the thoughts on valuation and the catalysts.</p>

When it comes to Jiangsu Hengrui Medicine (600276 CH), people would  also mention Hansoh Pharmaceutical (3692 HK), because its chairlady and CEO Zhong Huijuan is the wife of Hengrui’s Sun Piaoyang. Previously, Hansoh started with generic drugs (mainly first-to-market generic drugs), and has several blockbuster varieties with annual sales of more than RMB1 billion, such as zefei, pulaile, oulanning and so on. After more than 20 years of development, the Company has tablished a broad, diversified and leading drug portfolio in central nervous system (“CNS”) diseases, oncology, anti-infectives and diabetes. This article mainly analyzed the core products, the pipeline, the key risks, the thoughts on valuation and the catalysts.

Hansoh Pharmaceutical (3692.HK) - Insights on Core Products, Pipeline, Catalysts and Key Risks